Pharmadrug (G11) AI Stock Analysis

Pharmadrug

(Frankfurt:G11)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved cash burnCash burn has improved materially from prior years, reducing the immediate pace of liquidity depletion. Although cash flow remains negative, a lower burn rate can extend funding runway and create more time for management to improve operations or secure financing.

Negative Factors

No meaningful revenue scaleAn effectively nonexistent revenue base prevents the company from demonstrating product demand, operating scale, or a durable commercial engine. Negative gross profit further suggests current sales do not cover direct costs, leaving fixed expenses and future development dependent on outside funding.

Pharmadrug (G11) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 671.07K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.9
Beta (1Y): 26.20
Revenue Growth: ―
EPS Growth: -52.38%
Country: Germany
Employees: 9
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Pharmadrug Business Overview & Revenue Model

Company Description

Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived...

Pharmadrug Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:G11 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:INNO	44Neutral	CAD 8.55M	-6.57	-19.37%	―	-19.20%	42.54%
TSE:RVV	42Neutral	CAD 8.37M	-0.83	26.78%	―	―	90.84%
TSE:RAMM	42Neutral	CAD 1.19M	-0.13	-194.41%	―	-66.40%	31.38%

* Healthcare Sector Average

Performance Comparison

DE:G11 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:G11	Pharmadrug Inc.	0.01	-0.00	-12.50%
TSE:RVV	Revive Therapeutics	0.02	0.01	100.00%
TSE:INNO	Innocan Pharma Corporation	1.90	-16.10	-89.44%
TSE:RAMM	Ramm Pharma Corp	0.01	-0.01	-50.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pharmadrug AI Stock Analysis